Georgina Thorborn

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · 315 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Felice Rivellese, Anna E. A. Surace, Katriona Goldmann et al. · Nature Medicine · 2022 · 279 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients

Alessandra Nerviani, Maria Di Cicco, Arti Mahto et al. · Frontiers in Immunology · 2020 · 95 citations · Full text

Medicine, Immunology, Pathology +17

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

Felice Rivellese, Alessandra Nerviani, Giovanni Giorli et al. · The Lancet Rheumatology · 2023 · 68 citations · Full text

Medicine, Immunology, Pathobiology +15

Increased Sensitivity of CD4+ T-Effector Cells to CD4+CD25+ Treg Suppression Compensates for Reduced Treg Number in Asymptomatic HIV-1 Infection

Georgina Thorborn, Laura W. Pomeroy, Heidi Isohanni et al. · PLoS ONE · 2010 · 32 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16